Physician profile
John Kim
NPI 1659359263
$2,251.92
in general payments reported to CMS, 2019-2025
16 companies · $83.82 in 2025
The $83.82 reported for 2025 was less than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,137 · 2020: $163 · 2021: $178 · 2022: $284 · 2023: $181 · 2024: $227 · 2025: $83.82.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $491.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $490.98 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Tepha INC | $989.10 | 2019 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $407.81 | 2021-2025 | Xifaxan, Trulance |
| Abbvie INC. | $209.66 | 2019-2022 | |
| Abbott Laboratories | $125.00 | 2024 | Eterna |
| Amarin Pharma, INC. | $123.08 | 2020-2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $89.10 | 2020-2025 | Jardiance, Tradjenta |
| Astrazeneca Pharmaceuticals LP | $74.55 | 2019-2023 | Farxiga |
| Grifols USA, LLC | $74.22 | 2019-2021 | |
| Allergan, INC. | $41.05 | 2019-2020 | |
| Lilly USA, LLC | $29.19 | 2023 | Jardiance |
| Pharming Healthcare, INC. | $19.96 | 2022 | |
| Pfizer INC. | $14.98 | 2021 | |
| Janssen Pharmaceuticals, INC | $14.28 | 2020 | |
| Glaxosmithkline, LLC. | $13.58 | 2022 | |
| Nestle Healthcare Nutrition INC. | $13.50 | 2022 |
Show all 16 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Arbor Pharmaceuticals, INC. | $12.86 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw John Kim listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.